시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 전이성 HR+/HER2- 유방암 시장 보고서(2025년)
Metastatic HR+/HER2- Breast Cancer Global Market Report 2025
상품코드 : 1720829
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,319,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,134,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,949,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

전이성 HR+/HER2- 유방암 시장 규모는 향후 몇 년 동안 높은 성장세를 보일 것으로 예상됩니다. 예측 기간의 성장은 새로운 치료법의 채택 증가, 면역 치료의 사용 증가, 신흥 시장으로의 확장, 환자 옹호 및 지원 프로그램, 삶의 질 향상에 대한 관심에 기인한 것으로 볼 수 있습니다. 이 기간 동안 예상되는 주요 트렌드에는 차세대 시퀀싱(NGS), 액체 생검 기술, 바이오마커 발견, 세포 및 유전자 치료, 단일 클론 항체(mAb) 개발의 발전이 포함됩니다.

호르몬 대체 치료(HRT)에 대한 수요 증가는 향후 몇 년간 전이성 HR+/HER2- 유방암 시장의 확장을 주도할 것으로 예상됩니다. HRT는 일반적으로 폐경기 또는 호르몬 결핍이 발생할 때 체내 수치가 낮은 호르몬을 대체하거나 보충하는 데 사용되는 치료법입니다. HRT의 사용 증가는 치료 결과를 개선하는 효과, 기존 치료법에 비해 적은 부작용, 정밀 의학의 발전 등에 기인합니다. HRT는 내분비 치료의 효과에 영향을 주지 않으면서 안면홍조, 질 건조증 등 폐경기의 에스트로겐 결핍과 관련된 증상을 완화하여 전이성 HR+/HER2- 유방암 환자에게 도움을 줄 수 있습니다. HRT는 주로 암세포가 아닌 호르몬 불균형을 해결하기 때문에 암 치료를 받는 환자의 삶의 질을 향상시킵니다. 예를 들어, 2023년 10월 NHS England는 2022-23년 영국에서 2021-22년에 비해 47% 증가한 1,100만 건의 HRT 처방전이 발행되었다고 보고했습니다. 결과적으로 HRT의 사용 증가는 전이성 HR+/HER2- 유방암 시장의 성장에 기여하고 있습니다.

전이성 HR+/HER2- 유방암 시장에서 활동하는 주요 기업들은 치료 옵션, 시장 범위 및 적응증을 확대하기 위해 병용 치료을 개발하고 있습니다. 병용 치료에는 화학 치료, 표적 치료, 면역 치료, 호르몬 치료 또는 기타 접근법과 같은 두 가지 이상의 치료제를 동시에 사용하는 것이 포함됩니다. 이 전략은 서로 다른 경로를 표적으로 삼아 전반적인 치료 반응을 개선하고 암과 같은 단일 치료에 대한 내성 가능성을 줄임으로써 질병을 보다 효과적으로 치료하기 위해 고안되었습니다. 예를 들어, 2023년 7월 미국 제약 회사인 Merck & Co. 는 항 PD-1 치료제인 키트루다(펨브롤리주맙)와 FDA 승인 화학치료을 병용하는 3상 임상시험인 KEYNOTE-756을 발표했습니다. 이 임상시험은 고위험 초기 단계의 ER+/HER2- 유방암 환자의 병리학적 완전 반응(pCR) 비율을 크게 개선하여 1차 평가지표를 충족했습니다. KEYNOTE-756은 이러한 환자군을 대상으로 신보조치료 환경에서 면역 치료 치료을 사용해 통계적으로 유의미한 pCR 비율 개선을 보인 최초의 3상 임상시험입니다. 이 임상시험에서는 고위험 초기 단계의 ER+/HER2- 유방암 환자를 대상으로 키트루다와 화학치료을 신보조치료으로 사용한 후, 키트루다와 내분비 치료을 병용하는 보조치료을 시험했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Metastatic HR+/HER2- breast cancer is a form of breast cancer where the cancer cells have spread from the breast to other parts of the body. Treatment typically involves targeted therapies, hormonal treatments, and chemotherapy to manage disease progression and enhance patient outcomes.

The primary drugs used for metastatic HR+/HER2- breast cancer include paclitaxel, tamoxifen, vinblastine, raloxifene, docetaxel, and other medications. Paclitaxel is a chemotherapy drug that works by stabilizing microtubules, preventing cancer cells from dividing and growing. These treatments are often combined with other approaches such as radiation therapy, vitamin therapy, macrobiotic diets, homeopathy, and herbal medicine. They are used in various healthcare settings, including hospitals, clinics, and other medical facilities.

The metastatic HR+/HER2- breast cancer market research report is one of a series of new reports from The Business Research Company that provides metastatic HR+/HER2- breast cancer market statistics, including metastatic HR+/HER2- breast cancer industry global market size, regional shares, competitors with a metastatic HR+/HER2- breast cancer market share, detailed metastatic HR+/HER2- breast cancer market segments, market trends and opportunities, and any further data you may need to thrive in the metastatic HR+/HER2- breast cancer industry. This metastatic HR+/HER2- breast cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metastatic HR+/HER2-breast cancer market size has grown rapidly in recent years. It will grow from $9.91 billion in 2024 to $10.92 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth during the historic period can be attributed to increased awareness about early diagnosis, higher diagnosis rates, successes in clinical trials, pharmaceutical investments, and the growing adoption of combination therapies.

The metastatic HR+/HER2-breast cancer market size is expected to see strong growth in the next few years. It will grow to $15.94 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to the increasing adoption of novel therapies, a growing use of immunotherapy, expansion into emerging markets, patient advocacy and support programs, and a focus on improving quality of life. Key trends expected during this period include advancements in next-generation sequencing (NGS), liquid biopsy technologies, biomarker discovery, cell and gene therapies, and the development of monoclonal antibodies (mAbs).

The growing demand for hormone replacement therapy (HRT) is anticipated to drive the expansion of the metastatic HR+/HER2- breast cancer market in the coming years. HRT is a medical treatment used to replace or supplement hormones that are at lower levels in the body, commonly during menopause or when hormone deficiencies occur. The rising use of HRT is attributed to its effectiveness in improving treatment outcomes, fewer side effects compared to traditional therapies, and advances in precision medicine. HRT can assist metastatic HR+/HER2- breast cancer patients by relieving symptoms associated with estrogen deficiency during menopause, such as hot flashes and vaginal dryness, without affecting the efficacy of endocrine therapies. Since HRT primarily addresses hormone imbalances rather than cancerous cells, it ensures better quality of life for patients undergoing cancer treatment. For example, in October 2023, NHS England reported that 11 million HRT prescriptions were issued in England during 2022-23, a 47% increase compared to 2021-22. Consequently, the growing use of HRT is contributing to the growth of the metastatic HR+/HER2- breast cancer market.

Key companies operating in the metastatic HR+/HER2- breast cancer market are developing combination therapies to expand treatment options, market reach, and indications. Combination therapy involves using two or more therapeutic agents simultaneously, such as chemotherapy, targeted therapy, immunotherapy, hormone therapy, or other approaches. This strategy is designed to treat medical conditions more effectively by targeting different pathways, enhancing overall treatment response, and reducing the chance of resistance to a single treatment, such as cancer. For example, in July 2023, Merck & Co., Inc., a US-based pharmaceutical company, announced the Phase 3 KEYNOTE-756 trial, which evaluated KEYTRUDA (pembrolizumab), an anti-PD-1 therapy, combined with FDA-approved chemotherapy. The trial met its primary endpoint by significantly improving the pathological complete response (pCR) rate in patients with high-risk, early-stage ER+/HER2- breast cancer. KEYNOTE-756 is the first Phase 3 trial to show a statistically significant improvement in pCR rates using an immunotherapy regimen in the neoadjuvant setting for this patient population. The trial tested KEYTRUDA with chemotherapy as neoadjuvant treatment, followed by adjuvant KEYTRUDA plus endocrine therapy for high-risk, early-stage ER+/HER2- breast cancer.

In November 2023, Carrum Health, a US-based healthcare solutions provider, entered into a partnership with Texas Oncology to enhance affordable breast cancer care. Through this collaboration, Carrum Health plans to offer a bundled package for breast cancer treatment, including two years of coverage for chemotherapy, radiation, and symptom management from Texas Oncology. This partnership aims to provide high-quality, cost-effective care. Texas Oncology, a US-based provider, specializes in treating metastatic HR+/HER2- breast cancer.

Major players in the metastatic hr+/her2- breast cancer market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hengrui Medicine Co Ltd., MacroGenics Inc., Arvinas Inc., Olema Pharmaceuticals Inc., CytomX Therapeutics Inc., G1 Therapeutics Inc., Context Therapeutics Inc., Celcuity Inc., Sermonix Pharmaceuticals Inc., Ambrx Biopharma Inc., Carrick Therapeutics.

North America was the largest region in the dominated market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metastatic HR+/HER2- breast cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metastatic HR+/HER2- breast cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metastatic HR+/HER2- breast cancer market consists revenues earned by entities by providing services such as endocrine therapy, and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic HR+/HER2- breast cancer market also includes sales of CDK4/6 inhibitors, PI3K inhibitors, mTOR inhibitors, and chemotherapy agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metastatic HR+/HER2- Breast Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metastatic hr+/her2- breast cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for metastatic hr+/her2- breast cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metastatic hr+/her2- breast cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Metastatic HR+/HER2- Breast Cancer Market Characteristics

3. Metastatic HR+/HER2- Breast Cancer Market Trends And Strategies

4. Metastatic HR+/HER2- Breast Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Metastatic HR+/HER2- Breast Cancer Growth Analysis And Strategic Analysis Framework

6. Metastatic HR+/HER2- Breast Cancer Market Segmentation

7. Metastatic HR+/HER2- Breast Cancer Market Regional And Country Analysis

8. Asia-Pacific Metastatic HR+/HER2- Breast Cancer Market

9. China Metastatic HR+/HER2- Breast Cancer Market

10. India Metastatic HR+/HER2- Breast Cancer Market

11. Japan Metastatic HR+/HER2- Breast Cancer Market

12. Australia Metastatic HR+/HER2- Breast Cancer Market

13. Indonesia Metastatic HR+/HER2- Breast Cancer Market

14. South Korea Metastatic HR+/HER2- Breast Cancer Market

15. Western Europe Metastatic HR+/HER2- Breast Cancer Market

16. UK Metastatic HR+/HER2- Breast Cancer Market

17. Germany Metastatic HR+/HER2- Breast Cancer Market

18. France Metastatic HR+/HER2- Breast Cancer Market

19. Italy Metastatic HR+/HER2- Breast Cancer Market

20. Spain Metastatic HR+/HER2- Breast Cancer Market

21. Eastern Europe Metastatic HR+/HER2- Breast Cancer Market

22. Russia Metastatic HR+/HER2- Breast Cancer Market

23. North America Metastatic HR+/HER2- Breast Cancer Market

24. USA Metastatic HR+/HER2- Breast Cancer Market

25. Canada Metastatic HR+/HER2- Breast Cancer Market

26. South America Metastatic HR+/HER2- Breast Cancer Market

27. Brazil Metastatic HR+/HER2- Breast Cancer Market

28. Middle East Metastatic HR+/HER2- Breast Cancer Market

29. Africa Metastatic HR+/HER2- Breast Cancer Market

30. Metastatic HR+/HER2- Breast Cancer Market Competitive Landscape And Company Profiles

31. Metastatic HR+/HER2- Breast Cancer Market Other Major And Innovative Companies

32. Global Metastatic HR+/HER2- Breast Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metastatic HR+/HER2- Breast Cancer Market

34. Recent Developments In The Metastatic HR+/HER2- Breast Cancer Market

35. Metastatic HR+/HER2- Breast Cancer Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기